No booster for Emma as GSK’s Novavax deal is off

STUTTERING attempts by GlaxoSmithKline to join the Covid vaccine bonanza have suffered another setback.

A year ago GSK championed a tie-up with America’s Novavax – but the deal is now off.

The original agreement would have seen GSK provide ‘fill and finish’ manufacturing at its site in County Durham’s Barnard Castle (infamous as Dominic Cummings’ lockdown stomping ground).

GSK had planned to start working on the manufacture of up to 60 million doses of the jab from as early as May 2021. But Novavax spent last year working to gain regulatory approvals and GSK wasn’t prepared to reserve the factory capacity.

Boss Emma Walmsley said last week: ‘We stood ready to support it, but just because of the delays in its supply, that is no longer required.’

At least the deal was relatively small beer for GSK. Walmsley will hope that imminent final data on its main jab prospect, developed by France’s Sanofi, can boost its Covid efforts.

RUGBY fans were busy watching the Six Nations yesterday, but the tournament’s owner, CVC Capital, doesn’t fancy a scrum.

The private equity firm has been touted in the City as a suitor for The Hut Group. The online retailer has already attracted attention from rival buyout firms Advent International, Leonard Green & Partners and Apollo.

Dominic Murphy joined CVC as managing partner in 2019 from rival KKR, where he played a key role in investing in THG, but sources close to CVC said Murphy had snubbed an approach about a deal.

THG’s pummelled stock has held gains made when buyout reports emerged. Are investors betting that founder Matt Moulding will swiftly end its painful stint as a public company?